COMP <GO>
TLSA vs RLYB // RETURN ON INVESTED CAPITAL (ROIC)
Tiziana Life Sciences Ltd. (NASDAQ) VS. Rallybio Corporation (NASDAQ) • 15-METRIC TALLY: TLSA 1
— RLYB 1
■ METRIC PARITY
LAST: $0.67 (-16.25%) • MKT CAP: $85.3M
roic
—
LAST: $15.76 (+1.42%) • MKT CAP: $84.9M
roic
-35.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TLSA VS. RLYB)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TLSA | RLYB | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 34.90% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 4.13 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 3/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 27.5 | 40.9 | -13.40 | RLYB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $85.3M | $84.9M | $412.8K | TLSA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TLSA REV | RLYB REV | TLSA GROSS % | RLYB GROSS % | TLSA FCF | RLYB FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $858.0K | — | — | — | -$29.8M |
| FY 2024 | — | $636.0K | — | — | — | -$49.3M |
| FY 2023 | — | $221.0M | — | — | — | -$60.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TLSA // BETA —
RLYB // BETA —